Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DMPA-SC (subcutaneous depot medroxyprogesterone acetate) is a long-acting, progestin-only injectable contraceptive administered subcutaneously. It contains 104 mg of medroxyprogesterone acetate in a depot formulation and provides contraception for three months per injection. The mechanism of action involves suppression of ovulation by inhibiting the secretion of gonadotropins (luteinizing hormone and follicle-stimulating hormone), thickening cervical mucus to prevent sperm penetration, and thinning the endometrial lining to inhibit implantation. DMPA-SC is available as an all-in-one prefilled injection system (notably Sayana Press) that can be self-administered or given by healthcare providers. It is indicated for prevention of pregnancy and management of endometriosis-associated pain[2][4][5][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dmpa-sc.